Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Summit Therapeutics Inc.SMMT · Entity 3477 | Chief Scientific Officer | November 27, 2020 | December 02, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Summit Therapeutics Inc.
Report date November 27, 2020 · Filed December 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2020-11-30 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2020-11-27 · Exercise / conversion · Acquired 16,616 · Balance 16,616 F1: Represents shares of Common Stock received by the Reporting Person as a result of the exercise of stock options set forth in Table II, which shares were subsequently sold in the open market at prevailing market prices. Row 2 · 2020-11-27 · Exercise / conversion · Acquired 12,953 · Balance 29,569 F1: Represents shares of Common Stock received by the Reporting Person as a result of the exercise of stock options set forth in Table II, which shares were subsequently sold in the open market at prevailing market prices. Row 3 · 2020-11-27 · Sale · Disposed 29,569 · Balance 0 F2: The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.30 to $4.66. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range. Row 4 · 2020-11-30 · Exercise / conversion · Acquired 13,713 · Balance 13,713 F1: Represents shares of Common Stock received by the Reporting Person as a result of the exercise of stock options set forth in Table II, which shares were subsequently sold in the open market at prevailing market prices. Row 5 · 2020-11-30 · Sale · Disposed 13,713 · Balance 0 F3: The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.40 to $4.50. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.92 · Expires 2028-10-19 | Direct | 417,639 |
Reported balance
After 2020-11-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-27 · Other · Disposed 16,616 · Balance 417,639 F4: The option was granted on October 19, 2018. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.79 · Expires 2029-03-29 | Direct | 404,686 |
Reported balance
After 2020-11-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-11-27 · Other · Disposed 12,953 · Balance 404,686 F5: The option was granted on March 29, 2019. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.79 · Expires 2029-03-29 | Direct | 390,973 |
Reported balance
After 2020-11-30 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-11-30 · Other · Disposed 13,713 · Balance 390,973 F5: The option was granted on March 29, 2019. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Common Stock received by the Reporting Person as a result of the exercise of stock options set forth in Table II, which shares were subsequently sold in the open market at prevailing market prices.
F2: The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.30 to $4.66. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.
F3: The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.40 to $4.50. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.
F4: The option was granted on October 19, 2018. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date.
F5: The option was granted on March 29, 2019. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 30, 2020 Filed Dec 2, 2020 00:45 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | OtherStock Option (right to buy) · Derivative | 13,713 | $1.79 Strike: $1.79 | $24,546.27 |
DisclosureSEC source: 0000921895-20-003153 · form412566003_12012020.xml · derivative · entry 8 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,973 Underlying: Common Stock · 13,713 shares Expires 2029-03-29 F5 · derivative.exercise_date: The option was granted on March 29, 2019. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 00:45 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | SaleCommon Stock | 13,713 | $4.44 | $60,885.72 |
DisclosureSEC source: 0000921895-20-003153 · form412566003_12012020.xml · nonDerivative · entry 5 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.40 to $4.50. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 00:45 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | Exercise / conversionCommon Stock | 13,713 | $1.79 | $24,546.27 |
DisclosureSEC source: 0000921895-20-003153 · form412566003_12012020.xml · nonDerivative · entry 4 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of Common Stock received by the Reporting Person as a result of the exercise of stock options set forth in Table II, which shares were subsequently sold in the open market at prevailing market prices. Read SEC document |
| November 27, 2020 Filed Dec 2, 2020 00:45 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | OtherStock Option (right to buy) · Derivative | 12,953 | $1.79 Strike: $1.79 | $23,185.87 |
DisclosureSEC source: 0000921895-20-003153 · form412566003_12012020.xml · derivative · entry 7 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,686 Underlying: Common Stock · 12,953 shares Expires 2029-03-29 F5 · derivative.exercise_date: The option was granted on March 29, 2019. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date. Read SEC document |
| November 27, 2020 Filed Dec 2, 2020 00:45 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | OtherStock Option (right to buy) · Derivative | 16,616 | $1.92 Strike: $1.92 | $31,902.72 |
DisclosureSEC source: 0000921895-20-003153 · form412566003_12012020.xml · derivative · entry 6 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,639 Underlying: Common Stock · 16,616 shares Expires 2028-10-19 F4 · derivative.exercise_date: The option was granted on October 19, 2018. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date. Read SEC document |
| November 27, 2020 Filed Dec 2, 2020 00:45 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | SaleCommon Stock | 29,569 | $4.39 | $129,807.91 |
DisclosureSEC source: 0000921895-20-003153 · form412566003_12012020.xml · nonDerivative · entry 3 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.30 to $4.66. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 27, 2020 Filed Dec 2, 2020 00:45 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | Exercise / conversionCommon Stock | 12,953 | $1.79 | $23,185.87 |
DisclosureSEC source: 0000921895-20-003153 · form412566003_12012020.xml · nonDerivative · entry 2 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,569 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of Common Stock received by the Reporting Person as a result of the exercise of stock options set forth in Table II, which shares were subsequently sold in the open market at prevailing market prices. Read SEC document |
| November 27, 2020 Filed Dec 2, 2020 00:45 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | Exercise / conversionCommon Stock | 16,616 | $1.92 | $31,902.72 |
DisclosureSEC source: 0000921895-20-003153 · form412566003_12012020.xml · nonDerivative · entry 1 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,616 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of Common Stock received by the Reporting Person as a result of the exercise of stock options set forth in Table II, which shares were subsequently sold in the open market at prevailing market prices. Read SEC document |
| November 25, 2020 Filed Nov 26, 2020 00:51 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | OtherStock Option (right to buy) · Derivative | 12,070 | $1.92 Strike: $1.92 | $23,174.40 |
DisclosureSEC source: 0001193805-20-001473 · e620105_4-powell.xml · derivative · entry 9 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,255 Underlying: Common Stock · 12,070 shares Expires 2028-10-19 F5 · derivative.exercise_date: The option was granted on October 19, 2018. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date. Read SEC document |
| November 25, 2020 Filed Nov 26, 2020 00:51 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | SaleCommon Stock | 12,070 | $4.32 | $52,142.40 |
DisclosureSEC source: 0001193805-20-001473 · e620105_4-powell.xml · nonDerivative · entry 6 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · price: The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.40 to $4.21. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 25, 2020 Filed Nov 26, 2020 00:51 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | Exercise / conversionCommon Stock | 12,070 | $1.92 | $23,174.40 |
DisclosureSEC source: 0001193805-20-001473 · e620105_4-powell.xml · nonDerivative · entry 5 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of Common Stock received by the Reporting Person as a result of the exercise of stock options set forth in Table II, which shares were subsequently sold in the open market at prevailing market prices. Read SEC document |
| November 24, 2020 Filed Nov 26, 2020 00:51 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | OtherStock Option (right to buy) · Derivative | 11,374 | $1.92 Strike: $1.92 | $21,838.08 |
DisclosureSEC source: 0001193805-20-001473 · e620105_4-powell.xml · derivative · entry 8 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,325 Underlying: Common Stock · 11,374 shares Expires 2028-10-19 F5 · derivative.exercise_date: The option was granted on October 19, 2018. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date. Read SEC document |
| November 24, 2020 Filed Nov 26, 2020 00:51 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | SaleCommon Stock | 11,374 | $4.21 | $47,884.54 |
DisclosureSEC source: 0001193805-20-001473 · e620105_4-powell.xml · nonDerivative · entry 4 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.24 to $4.20. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 24, 2020 Filed Nov 26, 2020 00:51 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | Exercise / conversionCommon Stock | 11,374 | $1.92 | $21,838.08 |
DisclosureSEC source: 0001193805-20-001473 · e620105_4-powell.xml · nonDerivative · entry 3 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of Common Stock received by the Reporting Person as a result of the exercise of stock options set forth in Table II, which shares were subsequently sold in the open market at prevailing market prices. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:51 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | OtherStock Option (right to buy) · Derivative | 6,987 | $1.92 Strike: $1.92 | $13,415.04 |
DisclosureSEC source: 0001193805-20-001473 · e620105_4-powell.xml · derivative · entry 7 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,699 Underlying: Common Stock · 6,987 shares Expires 2028-10-19 F5 · derivative.exercise_date: The option was granted on October 19, 2018. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:51 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | SaleCommon Stock | 6,987 | $4.40 | $30,742.80 |
DisclosureSEC source: 0001193805-20-001473 · e620105_4-powell.xml · nonDerivative · entry 2 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.41 to $4.40. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:51 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | Exercise / conversionCommon Stock | 6,987 | $1.92 | $13,415.04 |
DisclosureSEC source: 0001193805-20-001473 · e620105_4-powell.xml · nonDerivative · entry 1 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of Common Stock received by the Reporting Person as a result of the exercise of stock options set forth in Table II, which shares were subsequently sold in the open market at prevailing market prices. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.